Ane Fullaondo

With a degree in Biology and a PhD in Genetics, she decided to make the leap from the laboratory to management. After seven years dedicated exclusively to basic science, she joined the Biosistemak project (Research Center on Chronicity of the Basque Country, an international benchmark in the study and analysis of the chronically ill) in 2013. She is currently the scientific director of Biosistemak.

Bernard Zalc

Relevant academic researcher at the French Institute of Medical and Health Research. The author has contributed significantly to research on the following topics: Oligodendrocytes and Myelin. The author has a hindex of 49, co-authored 115 publications and received 7797 citations. Bernard Zalc’s previous affiliations include Pierre-and-Marie-Curie University.

Catherine Lubetzki

Professor of Neurology at Sorbonne University and is medical director of the Paris Brain Institute. She is vice-president of the Sorbonne University Foundation. Catherine belongs to different committees and steering bodies such as ARSEP (French Multiple Sclerosis association for research) or the International Progressive MS Alliance Scientific Steering Committee.

Emilio Geijo Barrientos

Professor of Physiology at the Faculty of Medicine of the UMH. Researcher at the Institute of Neurosciences as principal investigator of the Research Group: Neurobiology of mental, neurodegenerative and neuro-oncological diseases. International leader in electrophysiological studies of cortical circuits.

Federico Pallardó

Member of the CIBERER steering committee (responsible for training), he directs the CIBERER-Biobank of the ISCIII. and expert in neurodegenerative diseases. He is currently a professor at the University of Valencia, being dean of the Faculty of Medicine and Dentistry of the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School. He has been director of the Central Research Unit, coordinating the basic research laboratories of INCLIVA for more than ten years. He is group leader of the CIBER in its rare diseases division since 2007.

Fernando de Castro

Senior Scientist of the CSIC and Principal Investigator of the Developmental Neurobiology Group-GNDe at the Cajal Institute-CSIC. His main research interests range from oligodendrogliogenesis and myelination to the pathophysiology of demyelinating diseases (multiple sclerosis, leukodystrophies) and the search for cellular and molecular mechanisms to effectively (re)myelinate. Current president of the Spanish Glial Network

Francisco Carratalá

Neuropediatrician at the Hospital Universitario San Juan de Alicante for 29 years and the first neurologist member of the European Neuropediatric Society (EPNS)

José María Moraleda

Coordinator of the Spanish network of advanced therapies (TERAV), for 11 years head of the Hematology Service and the Hematopoietic Transplant and Cell Therapy Unit of the Virgen de la Arrixaca University Hospital in Murcia, professor at the University of Murcia and president of the Spanish Society of Hematology and Hemotherapy (SEHH) (2013-2016)

Julián Isla

Software engineer at Microsoft, advisor to the European Medicines Agency and member of the 29 Foundation, father of a son affected by a neurodegenerative disease who carries out an important international activity to promote the use of AI and other technologies for the diagnosis and cure of these diseases

Marc Engelen

He is currently working in the Department of Pediatric Neurology and specifically in the center for white matter disorders at the VU University Medical Center (UMC), Amsterdam. Marc has an intense research activity in leukodystrophies, especially in adrenoleukodystrophy.

Mercedes Lachén

Navarra BIOMED researcher specialist in proteomics in neurodegenerative diseases

Nathalie Cartier

Director of the INSERM lab NeuroGenCell (Gene and cell Therapy for neurodegenerative diseases of adults and children) at the Paris Brain Institute (ICM) at the Pitié Salpêtrière Hospital in Paris. She acted as an investigator in the framework of the first gene therapy developed (in X-ALD) and her group is actively working on the development of gene therapies in neurodegenerative diseases. Recent awards: Grand Prix de la Fondation pour la Recherche médicale (2019), Grand prix de l’Académie des Sciences 2019.

Paul Orchard

Medical Director of the Inherited Metabolic and Storage Diseases Program and Professor in the Department of Pediatrics, Division of Cell Therapy and Blood and Marrow Transplantation at the University of Minnesota Hospital. Dr. Orchard’s focus is on the use of hematopoietic stem cell transplantation and other cell therapies for inherited metabolic disorders, with special interest in inherited leukodystrophies, mucopolysaccharidoses and osteopetrosis. His clinical research focuses on the evolution of novel and combination therapies to decrease toxicity and improve outcomes, with special interest in the use of gene therapy approaches, with extensive experience in leukodystrophies.

Pedro Carrascal

Current General Director of the Patients’ Organizations Platform (POP). Director of ADEMBI (Multiple Sclerosis Association of Bizkaia) for 25 years (until 2022), as well as Esclerosis Múltiple Euskadi and Esclerosis Múltiple España, positions he held simultaneously during those years.

Salvador Martínez

Director of the Instituto Neurociencias de Alicante (IN), UMH-CSIC (April 2016-November 2020), Professor of Human Anatomy Medicine Univ. Murcia and UMH (since 2004), Professor of the Master of IN (since 2004) and Pasteur Institute of Paris (since 2005), Full Professor and Professor of the Universities of Murcia and Miguel Hernández de Elche

Sara García Gil-Perotin

Neurologist at La Fe Hospital in Valencia and in charge of the follow-up and registry of MS patients transplanted with bone marrow progenitors, as a member of the ADWP of the EBMT

Silvia de Santis

Principal Researcher at the Institute of Neurosciences (CSIC-UMH), San Juan de Alicante

Verónica Cantarín

Exclusive dedication to neuropediatrics since 2009, PhD in 2021 with outstanding “Cum Lauden” by the Autonomous University of Madrid. In recent years I have focused my interest in the field of neuroimmunology and acquired brain injury where she carries out several research projects. Head of the CLINICAL GROUP GV23/ER/3 of the Center for Biomedical Research Network for Rare Diseases (CIBERER)-Instituto de Salud Carlos III.